Anivive

What Anivive does

Anivive Lifesciences, Inc. is a Long Beach, California-based pet pharmaceutical company founded in 2015 that combines AI software, biotechnology, and veterinary medicine to develop therapeutics and diagnostics for companion animals in disease areas with limited or no approved treatments (it cites that only 15% of pet diseases have an approved product). The company operates a portfolio anchored by Laverdia (verdinexor), the first FDA-approved oral tablet for canine lymphoma, distributed in partnership with Dechra Pharmaceuticals, alongside a pipeline of six investigational candidates spanning oncology (eBAT for hemangiosarcoma, osteosarcoma), fungal disease (Valley Fever and Blastomycosis vaccines, developed under USDA pathways), and viral infection (GC376 for feline infectious peritonitis).

The technology platform comprises AniviveSELECT, an AI-powered drug discovery engine analyzing over 1 billion datapoints across 300+ sources; SearchLight DNA, a 120-gene canine cancer genotyping test built with City of Hope and TGen over a 300+ billion datapoint genomic database; a deep convolutional neural network imaging module for Valley Fever detection; and AniviveTrial, a marketplace platform that connects pet owners to clinical trials and accelerates enrollment by 80%.

The business model blends pharmaceutical product sales (Laverdia through Dechra and MWI Animal Health), diagnostic testing services (SearchLight DNA via the engage.anivive.com portal), clinical trial marketplace transactions, government grants and contracts (FDA $500K, NIAID up to $33M), and licensing royalties on assets such as GC376. Customers span veterinary professionals, specialty oncology clinics, pet owners seeking advanced diagnostics or trial access, and government research agencies, with distribution extended into precision compounded medications through a partnership with Stokes Pharmacy.

Name

Anivive

Legal name

Anivive Lifesciences, Inc.

Website

https://anivive.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

11–50 employees

Short description

Anivive Lifesciences is a Long Beach-based pet pharmaceutical company that combines AI, biotechnology, and veterinary medicine to develop therapeutics and diagnostics for companion animal diseases with no approved treatments, selling the FDA-approved canine lymphoma drug Laverdia through Dechra and operating AI-powered platforms for drug discovery, genomic testing, and clinical trial enrollment.

Ownership category

akta.pro rank

Product category

Veterinary Pharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Medical Laboratories (621511)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836), Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Oncology & Specialty Therapeutics (HLAMAEAJ)

akta.pro secondary industries

Companion Animal Therapeutics (Rx) (HLAMAEAA), Molecular & Genetic Testing (Breed, Hereditary Disease, Oncology) (HLAMADAE), Oncology Diagnostics (Liquid/Tissue Biomarkers, Flow Cytometry) (HLAMADAJ)

Keywords

• Veterinary pharmaceuticals
• Animal health biotechnology
• Companion animal therapeutics
• Canine cancer diagnostics
• AI drug discovery

Headquarters

HQ city

Long Beach

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Pharmaceutical Product Sales: Sale of approved veterinary pharmaceutical products including LAVERDIA-CA1 (verdinexor) for canine lymphoma, distributed through Dechra.
2. Diagnostic Testing Services: SearchLight DNA genomic testing service for canine cancer providing tumor genotyping and actionable insights for personalized treatment plans.
3. Clinical Trial Marketplace: Platform connecting pet owners with clinical trials and supporting trial managers with recruitment and study management.
4. Licensing Royalties: Licensing of GC376 technology for both veterinary and potential human applications, including COVID-19 therapeutics development.
5. Government Grants: Research grants from government agencies including $500,000 FDA grant for canine cancer studies and NIAID contract worth up to $33M for Valley Fever vaccine development.

Go-to-market motion3 records

Distribution channels5 records

Marketing channels6 records

Core offering

Anivive develops and commercializes pharmaceutical products, diagnostics, and AI-driven software for companion animal health. Its portfolio includes FDA-approved LAVERDIA-CA1 (verdinexor) for canine lymphoma, the SearchLight DNA cancer genotyping test, the AniviveSELECT AI drug discovery platform, the AniviveTrial clinical trial marketplace, and a pipeline of investigational vaccines and therapeutics for conditions such as Valley Fever, FIP, hemangiosarcoma, blastomycosis, and osteosarcoma. The company combines biotech, veterinary medicine, and proprietary AI software to address pet diseases that lack approved treatments.

Product overview

Anivive is a next-generation animal health company combining AI software, biotech, and veterinary medicine to address unmet medical needs in companion animals. The company offers a diversified portfolio including FDA-approved Laverdia (verdinexor) for canine lymphoma, multiple investigational treatments in development (Valley Fever vaccine, FIP treatment GC376, eBAT for hemangiosarcoma), and technology platforms including SearchLight DNA genomic testing, AniviveSelect AI-powered drug discovery, AniviveTrial clinical trial marketplace, and specialty pathology services. The product ecosystem is unified by AI-powered technology spanning from drug discovery through clinical trials to treatment delivery.

Differentiator

Problem solved

Functional benefit

Brands

• Laverdia: FDA-approved treatment (verdinexor tablets) for canine lymphoma, available via Dechra.
• SearchLight DNA
• AniviveSELECT
• AniviveTrial
• AniviveCARES

Quantifiable outcome

• eBAT demonstrated increase in 6-month survival from <40% to approximately 70% in hemangiosarcoma studies
• +3 more outcomes

Named customers4 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature6 records

Partnerships

Eleven partnerships are on record, tiered core, major and supporting.

• Tufts UniversitycoreStrategic or Co-development Partner · 9 July 2021Multi-site clinical study collaboration for LAVERDIA-CA1 research involving over 100 dogs to support development and approval of new pet cancer treatments.
• City of HopecoreStrategic or Co-development PartnerResearch collaboration for SearchLight DNA genomic test development; City of Hope contributes expertise in cancer research and genomics.
• TGen (Translational Genomics Research Institute)coreStrategic or Co-development PartnerResearch collaboration for SearchLight DNA genomic test; TGen provides genomics research expertise for canine cancer precision medicine.
• Valley Fever Center for Excellence at University of Arizona College of MedicinecoreStrategic or Co-development PartnerCollaboration with Dr. John Galgiani's research team for Valley Fever vaccine development and research.
• Petco LovemajorGTM or Marketing PartnerJoint initiative with Rob Gronkowski and Anivive to champion the fight against Valley Fever, supporting pet owner awareness and access to innovative care.
• MWI Animal HealthmajorChannel Partner/ Reseller/ DistributorCollaboration to provide veterinarians with Anivive's lymphoma treatment products through MWI's veterinary distribution network.
• Dechra PharmaceuticalscoreChannel Partner/ Reseller/ DistributorExclusive distribution partner for LAVERDIA-CA1 (verdinexor), making the FDA-approved canine lymphoma treatment available through Dechra's distribution network.
• Stokes PharmacymajorChannel Partner/ Reseller/ DistributorPartnership to make precision medicine more accessible by seamlessly connecting SearchLight DNA genomic insights with compounded medications from Stokes Pharmacy.
• Kansas State UniversitysupportingStrategic or Co-development PartnerAcademic research partner for FIP studies and publications.
• University of California, DavissupportingStrategic or Co-development PartnerField tests conducted at UC Davis for GC376 FIP treatment; academic research partner.
• Wichita State UniversitysupportingStrategic or Co-development PartnerAcademic research partner for FIP studies and publications.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Zoetis: Zoetis is the largest global animal health company with a broad pharmaceutical and diagnostics portfolio across companion and livestock animals. Anivive competes with Zoetis in veterinary oncology and parasiticide adjacencies but operates at a far smaller scale.
• Elanco Animal Health: Elanco is a top-tier global animal health company offering pharmaceuticals, vaccines, and diagnostics for companion animals and livestock. It competes with Anivive in the same end markets but with a far larger commercial infrastructure.
• IDEXX Laboratories: IDEXX is the dominant veterinary diagnostics company, offering reference lab services and in-clinic instruments. SearchLight DNA overlaps with IDEXX's oncology and genetic testing offerings, although Anivive focuses specifically on canine cancer genomics.
• Virbac: Virbac is a global animal health company with a companion-animal focus on dermatology, parasitology, and specialty therapeutics. It is comparable in targeting veterinary specialists but operates at a meaningfully larger scale than Anivive.
• Phibro Animal Health: Phibro develops and markets animal health pharmaceuticals and nutrition products with a livestock-leaning portfolio but growing companion-animal exposure. Comparable as a mid-sized animal-health company developing differentiated therapeutics.
• Antech Diagnostics (Mars Petcare): Antech is the largest US veterinary reference lab network, offering specialty diagnostics including oncology and genomics. It competes with SearchLight DNA in the canine cancer diagnostic workflow, scaled across thousands of clinics via Mars Petcare's veterinary footprint.

Direct peers

• Dechra Pharmaceuticals: Dechra is Anivive's exclusive distribution partner for LAVERDIA and also a direct peer in companion-animal specialty pharmaceuticals (endocrinology, dermatology, critical care). The partnership-plus-competition dynamic makes Dechra a unique comparator.

Emerging players

• Heska (now part of Antech/Mars Petcare): Heska specialized in veterinary in-clinic diagnostics before being acquired by Antech/Mars Petcare. It is comparable to Anivive's SearchLight DNA diagnostic testing business, particularly in specialty reference lab services.
• ImpriMed: ImpriMed provides AI-driven personalized medicine for veterinary cancer patients, including canine lymphoma drug response prediction. It is a direct emerging peer to Anivive's SearchLight DNA precision oncology offering.
• FidoCure (One Health Company): FidoCure offers genomic testing and targeted therapy recommendations for dogs with cancer, directly comparable to SearchLight DNA. It is an emerging precision-oncology peer operating at an earlier stage than Anivive.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Subsidiaries1 record

Funding overview

Funding rounds3 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Anivive